U.S. Bancorp reported a decline in revenue and net interest income for Q1 2024, but beat adjusted earnings expectations. FY24 guidance was also lowered.
Abbott Laboratories surpasses expectations with Q1 sales hitting $9.96B, a 10.8% rise driven by robust performance in Medical Devices, Established Pharmaceuticals, Nutrition, and Diagnostics. CEO Robert Ford boosts full-year sales outlook amidst strong Q1 growth.
Lasting protection against shingles for adults over 50 with GSK's RZV vaccine. New data from ZOSTER-049 trial reveals over a decade of high efficacy. Plus, GSK's oral antibiotic, gepotidacin, shows promising results for uncomplicated gonorrhea treatment.
Investors remain on edge as geopolitics continue to shape market trends, with Israel mulling a response to Iran while the U.S. and key allies explore further sanctions against Tehran.
Northern Trust shares are trading lower following first-quarter FY24 financial results. Sales declined 6% Y/Y to $1.65 billion, missing the analyst consensus of $1.75 billion. Adjusted net interest margin for the quarter contracted one basis points Y/Y to 1.61%.
Exxon Mobil awarded a large contract to TechnipFMC in Guyana, to supply subsea production systems for the Whiptail project. The project is worth $12.7B and will target an estimated resource base of over 850M barrels of oil.
Johnson & Johnson reports Q1 results: adjusted EPS $2.71 (up 12.4% Y/Y), sales $21.38B (up 2.3% Y/Y). Explore pharma giant's robust performance, including strong growth in Innovative Medicine and medical devices sales.